Amid US Ordeal, Moderna Wins EU Approval for Flu/COVID-19 Combo Shot

Why It Matters

EU clearance gives Moderna a foothold in the lucrative senior‑vaccines market and validates its mRNA flu platform, while the ongoing U.S. regulatory impasse could delay revenue growth and affect investor confidence.

Key Takeaways

• EU approves Moderna's flu/COVID combo for ages 50+ across 27 states
• Combo includes mNEXSPIKE COVID shot and investigational flu vaccine mRNA‑1010
• FDA has refused to review mRNA‑1010, delaying US launch
• Phase 3 showed mRNA‑1010 26.6% more effective than standard flu shot
• Approval may boost Moderna's revenue and mRNA platform credibility

Pulse Analysis

The European Commission’s endorsement of mCOMBRIAX marks a pivotal moment for Moderna, showcasing the company’s ability to navigate divergent regulatory landscapes. By securing approval for a dual‑target vaccine, Moderna not only expands its product portfolio but also taps into the growing demand for streamlined immunization solutions among older adults, a demographic that accounts for a sizable share of flu‑related hospitalizations in Europe. This regulatory success underscores the EU’s willingness to embrace mRNA technology beyond COVID‑19, potentially accelerating broader adoption of mRNA‑based therapeutics.

mCOMBRIAX combines the next‑generation COVID‑19 antigen mNEXSPIKE with the flu candidate mRNA‑1010, which recently posted a 26.6% efficacy edge over the best‑available seasonal flu shot in a Phase 3 study of participants aged 50 and up. The trial’s robust results suggest the combo could deliver superior protection against two high‑impact respiratory viruses with a single injection, simplifying logistics for healthcare providers and improving patient compliance. Market analysts project that a successful rollout could capture a meaningful share of the European senior‑vaccines market, estimated at several hundred million doses annually, adding a new revenue stream for Moderna’s mRNA platform.

In contrast, the U.S. FDA’s refusal to file a review for mRNA‑1010 highlights the regulatory uncertainty that still shadows Moderna’s flu ambitions stateside. The agency’s demand for a more rigorous, well‑controlled trial against the current standard of care has delayed the U.S. filing of the combo vaccine, creating a timing gap between the two markets. This divergence may pressure Moderna to allocate additional resources to satisfy U.S. data requirements, potentially postponing commercial launch and affecting short‑term earnings. Nonetheless, the eventual FDA decision could set a precedent for future mRNA flu products, influencing the competitive dynamics of the broader vaccine industry.